Alexion Pharma Canada Corp.

Alexion Pharma Canada Corp. currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. However, the company is a current subsidiary of AstraZeneca PLC, which provides a framework for its climate commitments and emissions data.

AstraZeneca PLC, the parent company, has set ambitious climate targets that are cascaded down to Alexion Pharma Canada Corp. These initiatives include commitments to reduce greenhouse gas emissions across all scopes, with a focus on achieving net-zero emissions by 2025 for its global operations. The emissions data and reduction targets from AstraZeneca PLC are relevant for understanding the environmental impact and commitments of Alexion Pharma Canada Corp.

While specific reduction targets for Alexion Pharma Canada Corp. are not detailed, the overarching goals from AstraZeneca PLC include significant reductions in Scope 1, 2, and 3 emissions, aligning with industry standards and the Science Based Targets initiative (SBTi). This commitment reflects a proactive approach to addressing climate change and reducing the carbon footprint associated with their operations.

In summary, while Alexion Pharma Canada Corp. does not have specific emissions data or reduction targets available, it operates under the climate commitments and initiatives set forth by its parent company, AstraZeneca PLC, which are designed to drive substantial reductions in carbon emissions and promote sustainability within the pharmaceutical industry.